Clinical trials: Tremelimumab
Mesothelioma
Neoadjuvant Durvalumab and Tremelimumab With and Without Chemotherapy for Mesothelioma
Objectives: The investigators will test whether combination of chemoimmunotherapy or dual agent immunotherapy alone improves efficacy for patients with MPM.
- Trial name
- NCT05932199
- Testing
- Durvalumab / tremelimumab, Platinum cisplatin or carboplatin and pemetrexed chemotherapy plus durvalumab/tremelimumab
- Where
- 2 sites in United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Baylor College of Medicine
Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8
Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial
This phase II trial tests the impact of biomarkers in predicting initial treatment (first-line) PD1 or PD-L1 (PD[L]-1)-based immunotherapy response and in selecting second-line treatment in patients with stage IIIB-IV non-small…
- Conditions
- Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
- Trial name
- NCT07288034
- Testing
- Adagrasib, Anti-PD-L1 Monoclonal Antibody, Anti-PD1 Monoclonal Antibody
- Where
- 13 sites in United States
- Volunteers
- 535 people
- Sponsor
- City of Hope Medical Center
Head and Neck Squamous Cell Carcinoma
Durvalumab Plus Tremelimumab Combined With Proton Therapy for HNSCC
Clinical Phase: phase II single arm study Primary Objectives: Response rate Number of Subjects: 27 patients Study Population: recurrent or metastatic head and neck squamous cell carcinoma Investigational Product(s), Dose, and…
- Trial name
- NCT03450967
- Testing
- Durvalumab Plus Tremelimumab
- Where
- South Korea
- Volunteers
- 31 people
- Sponsor
- Samsung Medical Center
Cancer
A Phase II Study of Durvalumab Treatment - Substudy A: In Patients Who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity - Substudy B: For Continued Treatment (+/- Tremelimumab) of Patients Previously Enrolled to Completed CCTG Studies
I238A: The purpose of this study is to find out what effects being treated with durvalumab has on cancer. The researchers doing this study also want to evaluate if prednisone (a type of steroid), when given together with…
- Trial name
- NCT03847649
- Testing
- Durvalumab, Prednisone, Tremelimumab
- Where
- 11 sites in Canada
- Volunteers
- 60 people
- Sponsor
- Canadian Cancer Trials Group
Biliary Tract Cancer (CCA), Intrahepatic Cholangiocarcinoma
Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer
This is an interventional, prospective multicenter, open-label, phase II study in patients after curative surgery for BTC in a classic adjuvant situation, consisting of a two arm feasibility pilot part with a randomized…
- Conditions
- Biliary Tract Cancer (CCA), Intrahepatic Cholangiocarcinoma, Hilar Cholangiocarcinoma, Distal Cholangiocarcinoma
- Trial name
- NCT05239169
- Testing
- Durvalumab, Tremelimumab, Capecitabine
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Colorectal Cancer, Liver Metastases
Synergism of Immunomodulation and Tumor Ablation
This is a single-arm, open-label, multi-center early phase II study. This proof of concept study will investigate whether the combined use of local tumor ablation/radiation plus immunomodulating drugs may induce a significant…
- Trial name
- ILOC (NCT03101475)
- Testing
- Durvalumab (MEDI4736), Tremelimumab, Sterotactic body radiation therapy (SBRT)
- Where
- 10 sites in Austria, France and 4 more
- Volunteers
- 22 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Hepatocellular Carcinoma, Biliary Tract Cancer
Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer
This research study is studying a combination of drugs as a possible treatment for Hepatocellular Carcinoma or Biliary Tract Cancer. The interventions involved in this study are: Durvalumab Tremelimumab Radiation Therapy
- Trial name
- NCT03482102
- Testing
- Tremelimumab, Durvalumab, Radiation
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Massachusetts General Hospital
Hepatocellular Carcinoma
A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)
Hepatocellular carcinoma (HCC) is a common cancer worldwide and a leading cause of cancer-related death. The majority of participants first presenting with HCC have advanced unresectable or metastatic disease.
- Trial name
- LIVIGNO-2 (NCT06109272)
- Testing
- Livmoniplimab, Budigalimab, Durvalumab
- Where
- 37 sites in United States, France and 4 more
- Volunteers
- 89 people
- Sponsor
- AbbVie
Stage II-IVB Operable HNSCC Oral Cavity, Hypopharynx
Window of Opportunity Trial of Durvalumab (MEDI4736) or Durvalumab/Tremelimumab as Neoadjuvant Chemotherapy to Identify Immune Dynamics in Surgically Resectable Head and Neck Cancer Patients.
This is a phase II randomized, open label study of durvalumab with/ without tremelimumab as neoadjuvant therapy and durvalumab maintenance after SoC RTx with/without cisplatin as post-surgical adjuvant therapy in treatment naïve…
- Conditions
- Stage II-IVB Operable HNSCC Oral Cavity, Hypopharynx, Oropharynx, Larynx
- Trial name
- NCT03737968
- Testing
- Durvalumab, durvalumab + tremelimumab
- Where
- South Korea
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Yonsei University
Prostate Cancer
Prostate Cancer Biomarker Enrichment and Treatment Selection
The purpose of the pre-study screening is to test for DNA abnormalities or biomarkers.
- Trial name
- NCT03385655
- Testing
- Adavosertib, Savolitinib, Darolutamide
- Where
- 11 sites in Canada
- Volunteers
- 200 people
- Sponsor
- Canadian Cancer Trials Group
Unresectable Hepatocellular Carcinoma
Himalaya Early Access Program
To provide early access (i.e., before marketing authorisation) to tremelimumab 300 mg IV administered once on Day 1 of Cycle 1 plus durvalumab 1500 mg IV followed by durvalumab 1500 mg IV Q4W monotherapy in patients with…
- Trial name
- NCT05345678
- Testing
- Durvalumab, Tremelimumab
- Where
- 4 sites in United States
- Sponsor
- AstraZeneca
Tumor, Solid
Durvalumab and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid Tumors
This study will examine whether patients with relapsed/refractory solid tumors harboring evidence of somatic hypermutation (intermediate versus high tumor mutational burden) will exhibit improvement in disease progression-free…
- Trial name
- NCT03911557
- Testing
- Durvalumab and Tremelimumab
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- John L. Villano, MD, PhD
Small Cell Lung Carcinoma
A Study of Durvalumab Plus Tremelimumab With Chemotherapy in Untreated ES-SCLC
This study is designed to evaluate the safety and tolerability of durvalumab and tremelimumab in combination with intravenous (IV) carboplatin plus (+) etoposide in new patients with extensive-stage small cell lung cancer…
- Trial name
- NCT03963414
- Testing
- Durvalumab + Tremelimumab in combination with carboplatin and etoposide, Durvalumab in combination with carboplatin and etoposide
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Nebraska
Advanced Hepatocellular Carcinoma
Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)
This study will assess the safety and efficacy of Single Tremelimumab Regular Interval Durvalumab (STRIDE) as first-line therapy in participants with advanced unresectable HCC.
- Trial name
- SIERRA (NCT05883644)
- Testing
- Durvalumab, Tremelimumab
- Where
- 40 sites in United States, France and 8 more
- Volunteers
- 111 people
- Sponsor
- AstraZeneca
Renal Cell Carcinoma
Renal Adjuvant MultiPle Arm Randomised Trial
RATIONALE: The current global standard of care after nephrectomy for localised RCC therefore remains active monitoring (i.e., observation by clinical and radiological means).
- Trial name
- RAMPART (NCT03288532)
- Testing
- Durvalumab, Tremelimumab
- Where
- 35 sites in United Kingdom
- Volunteers
- 1,750 people
- Sponsor
- University College, London
Bladder Cancer
Study of CP-675,206 in Bacillus Calmette-Guerin (BCG)-Resistant Bladder Cancer
The purpose of this study is to find out the highest safe dose of the investigational drug CP-675,206 when given in combination with BCG therapy to patients who have experienced recurrent superficial bladder cancer after standard…
- Trial name
- NCT00880854
- Testing
- BCG and CP-675,206
- Sponsor
- University of Wisconsin, Madison
Resectable Gastric or Gastroesophageal Junction Adenocarcinoma
Trial of Neoadjuvant Durvalumab Plus Docetaxel, Oxaliplatin, S-1 Followed by Surgery and Adjuvant Durvalumab Plus S-1 Chemotherapy in Potentially Resectable MMR Proficient Gastric or Gastroesophageal Junction Adenocarcinoma
Neoadjuvant durvalumab (MEDI4736) plus docetaxel, oxaliplatin, S-1 (DOS) followed by surgery and adjuvant durvalumab plus S-1 chemotherapy in potentially resectable MMR proficient (pMMR) gastric or gastroesophageal junction (GEJ)…
- Trial name
- NCT04221555
- Testing
- Docetaxel, Oxaliplatin, S-1 and Durvalumab, Durvalumab and Tremelimumab
- Where
- South Korea
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Asan Medical Center
Locally Advanced or Metastatic Hepatoceullar Carcinoma
Comparison of Atezolizumab/Bevacizumab Versus Durvalumab/Tremelimumab (STRIDE) Protocols in Locally Advanced or Metastatic Hepatocellular Carcinoma Among Patients in Sohag
This retrospective observational study compares two first-line immunotherapy-based treatment regimens used for adults with locally advanced or metastatic hepatocellular carcinoma (HCC) at Suhag Cancer Center, Egypt.
- Trial name
- HCC (NCT07669597)
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Sohag Oncology Center
HCC, Tace
Partial Immune-boost TACE in unrEseCTable HCC Patients Under Systemic Treatment
Study Objectives： Atezolizumab (anti-programmed death-ligand 1; anti-PD-L1) combined with bevacizumab (anti-vascular endothelial growth factor; anti-VEGF) or Durvalumab (anti-programmed death-ligand 1; anti-PD-L1) combined with…
- Conditions
- HCC, Tace, Immunotherapy
- Trial name
- EXPECT (NCT07168668)
- Testing
- Transarterial chemoembolization, durvalumab and tremelimumab
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Chang Gung Memorial Hospital
Esophageal Adenocarcinoma
RICE: Radio-Immuno-Chemotherapy of Cancer of the Esophagus
A phase II trial to evaluate safety and efficacy of adding durvalumab (MEDI4736) to standard neoadjuvant radiochemotherapy and of adjuvant durvalumab +/- tremelimumab in locally advanced esophageal adenocarcinoma and to evaluate…
- Trial name
- RICE (NCT04159974)
- Testing
- Durvalumab 50 MG/ML, Tremelimumab
- Where
- 2 sites in Germany
- Volunteers
- 56 people
- Sponsor
- University of Cologne